Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0WH4L
|
|||
Former ID |
DNCL003119
|
|||
Drug Name |
AVN 211
|
|||
Indication | Schizophrenia [ICD-11: 6A20] | Phase 2/3 | [1] | |
Company |
Avineuro Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 6 receptor (HTR6) | Target Info | Modulator | [2] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Serotonergic synapse | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | |||
Reactome | Serotonin receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.